ORPHA:306547
Porencephaly-microcephaly-bilateral congenital cataract syndrome
Publications
15
21.7th percentile
Trials
0
Interventional, condition-specific
Researchers
140
Distinct authors in sample
Gene link
JAM3
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic, central nervous system syndrome characterized by bilateral cataracts and severe hemorrhagic destruction of the brain parenchyma with associated massive cystic degeneration, enlarged ventricles and subependymal calcification. Patients typically present generalized spasticity, increased deep tendon reflexes and . and renal anomalies have also been reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013394
- OMIM:613730
- UMLS:C3151000
Additional Mondo synonyms (1)
porencephaly-microcephaly-bilateral congenital cataract syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — JAM3
- LiteraturePresent
15 matched papers (6 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (JAM3).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
15
15 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
15 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
6 in the last 10 years · high confidence · 21.7th percentile (publications denominator)
Phrase hits: 15 · MeSH hits: 0
Who's working on it?
140
Distinct author names in 15 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Azevedo RDSDS2 papers · 2025
Hospital Geral de Belém, Belém 66050-450, PA, Brazil.
Papers in Europe PMC - 02Abeche AM1 paper · 2025
Brazilian Teratogen Information System, SIAT, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.
Papers in Europe PMC - 03Abrams TA1 paper · 2021
Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Papers in Europe PMC - 04Al-Hayek A1 paper · 2010Papers in Europe PMC
- 05Bardeesy N1 paper · 2021
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. Brian_Wolpin@dfci.harvard.edu Bardeesy.Nabeel@mgh.harvard.edu.
Papers in Europe PMC - 06Barnett C1 paper · 2018
Paediatric and Reproductive Genetics Unit, South Australian Clinical Genetics Service, Women's and Children's Hospital/SA Pathology, SA, Australia.
Papers in Europe PMC - 07Barreto ARF1 paper · 2025
Hospital Universitário Walter Cantídio (HUWC), Radiology Department and Universidade Federal do Ceará (UFC), Fortaleza 60020-181, CE, Brazil.
Papers in Europe PMC - 08Batta AK1 paper · 1999Papers in Europe PMC
- 09Bhattacharya A1 paper · 2013
Department of Plastic and Reconstructive Surgery, IPGME & R, Kolkata, India.
Papers in Europe PMC - 10Borges BDCB1 paper · 2025
Secretaria de Estado de Saúde do Acre (SESACRE), Rio Branco 69900-376, AC, Brazil.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06901934·NOT YET RECRUITING·JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes
Conditions: Urothelial Carcinoma Bladder·Matched via recall expansion
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Porencephaly-microcephaly-bilateral congenital cataract syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Porencephaly-microcephaly-bilateral congenital cataract syndrome" OR "JAM3"
Recall-expansion terms: JAM3
Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:47:51.899Z